We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Compounder Warned for Mixing Unapproved Drugs, GMP Violations

Compounder Warned for Mixing Unapproved Drugs, GMP Violations

July 11, 2014

The FDA warned another compounding pharmacy for mixing unapproved drugs and for poor quality, with Pharmacy Creations becoming the latest compounder to challenge agency enforcement of its activities.

The company was warned for its defiant response to an August 2013 inspection of its Randolph, N.J., facility, according to the warning letter posted online. Among the problems found at the plant, Pharmacy Creations was making drugs without a prescription — a common finding among larger compounding pharmacies.

The agency was further dismayed that Pharmacy Creations was compounding domperidone drug products, despite prior agency warnings in 2006 and 2008.

Domperidone is sometimes used in anti-vomiting treatments, but it is not approved by the FDA due to potential health risks.

FDA investigators also noted several quality violations. For example, the company produces sterile injectable drugs in multiple-dose containers without a preservative, which could increase the risk of infections, the June 23 letter says.

Pharmacy Creations did not test samples of drugs for strength, purity and quality and failed to test each batch to determine if it was sterile or pyrogen-free. Both of these are repeat violations from a 2006 warning letter, the agency said.

The letter recommends that the pharmacy conduct a comprehensive assessment of its quality system and hire a third-party consultant to help.

Pharmacy Creations responded to an August 2013 Form 483 by saying that it abides by U.S. Pharmacopeia (USP) regulations.

This is an oft-cited defense among compounders to agency inspection findings, signaling that such facilities are pushing back against being evaluated based on FDA regulations.

Medaus made the same response when it was warned by the agency earlier this year for unsanitary processing procedures. The Birmingham, Ala., pharmacy was hit with a warning letter for technicians performing aseptic processing with exposed skin, but the facility responded its procedures meet USP regulations.

Compounders have also complained that the agency is retroactively applying the 2013 Drug Quality and Security Act, which gave the FDA new authority to oversee compounding pharmacies.

The agency cited the law when it warned Pharmacy Creations, even though the inspection took place several months before the law was finalized in November. Pharmacy Creations is the eleventh compounder to receive a warning letter since passage of DQSA.

Per the new law, the agency issued guidance establishing an interim good manufacturing practice framework for large compounders that register with the FDA and finalized guidance on the enforcement of smaller, traditional compounders.

Pharmacy Creations is developing a response to the letter, Susan Brichler Trujillo, an attorney for the compounder said.

The company wants the FDA to immediately close out the matter “due to actions Pharmacy Creations has taken in the 10 months since the August 2013 inspection,” Trujillo said.

Avoid a warning letter and ensure that you’re producing sterile products, order Manufacturing Sterile Products to Meet EU and FDA Guidelines today!

Pharmaceuticals Quality GMPs Inspections and Audits

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing